Invesco Biotechnology & Genome ETF
PBE
104 hedge funds and large institutions have $94.1M invested in Invesco Biotechnology & Genome ETF in 2026 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 22 increasing their positions, 36 reducing their positions, and 8 closing their positions.
94% more capital inflows, than outflows
Capital inflows: $6.06M | Capital outflows: $3.12M
88% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 8
4% more funds holding
Funds holding: 100 → 104 (+4)
1.14% more ownership
Funds ownership: 32.88% → 34.02% (+1.1%)
39% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.38M |
| 2 |
LPL Financial
San Diego,
California
|
+$460K |
| 3 |
DAS
Dynamic Advisor Solutions
Phoenix,
Arizona
|
+$445K |
| 4 |
AWM
Axxcess Wealth Management
Carlsbad,
California
|
+$389K |
| 5 |
Jane Street
New York
|
+$388K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$728K |
| 2 |
GKWIM
Gerber Kawasaki Wealth & Investment Management
Santa Monica,
California
|
-$294K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$294K |
| 4 |
BAM
BOS Asset Management
Springfield,
Illinois
|
-$203K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$165K |
PBE Hedge Fund Activity: Q2 2026 in Review
104 of the 8,352 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q2 2026, worth a combined $94.1M — up 16% from $81M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new PBE positions and 8 closed out — a net gain of 7 holders — while 22 added to existing stakes and 36 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $1.38M. The largest seller was Royal Bank of Canada, cutting an estimated $728K.
- 104 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q2 2026, up from 100 in Q1 2026.
- Funds reported $94.1M of Invesco Biotechnology & Genome ETF stock for Q2 2026, up 16% quarter-over-quarter.
- 15 funds opened new Invesco Biotechnology & Genome ETF positions in Q2 2026 and 8 closed out, a net change of +7 holders.
- The largest Invesco Biotechnology & Genome ETF buyer in Q2 2026 was Morgan Stanley, an estimated $1.38M added.
- The largest Invesco Biotechnology & Genome ETF seller in Q2 2026 was Royal Bank of Canada, an estimated $728K sold.
Based on aggregated 13F filings for Q2 2026.